1. Targeted delivery of quercetin using gelatin/starch/Fe 3 O 4 nanocarrier to suppress the growth of liver cancer HepG2 cells.
- Author
-
Asl AM, Abdouss M, Kalaee MR, Homami SS, and Pourmadadi M
- Subjects
- Humans, Hep G2 Cells, Drug Liberation, Cell Proliferation drug effects, Magnetite Nanoparticles chemistry, Particle Size, Mice, Drug Delivery Systems, Animals, X-Ray Diffraction, Cell Survival drug effects, Quercetin pharmacology, Quercetin chemistry, Gelatin chemistry, Starch chemistry, Liver Neoplasms drug therapy, Liver Neoplasms pathology, Drug Carriers chemistry
- Abstract
To suppress HepG2 liver cancer cells, a nanocarrier (NC) consisting of Fe
3 O4 , Gelatin (G), and Starch (S) was synthesized and characterized for targeted delivery of Quercetin (QC) drug. The spectra obtained from X-ray diffraction (XRD) and Fourier transform infrared (FTIR) demonstrated that the nanoparticles (NP) in the NC are well-interconnected to each other and have formed a regular structure. Also, field emission scanning electron microscopy (FE-SEM) indicates a smooth and homogeneous surface of the synthesized NC. The results of the vibrating sample magnetometer (VSM) also corroborated the correctness of the synthesis of Fe3 O4 NPs and Gelatin/Starch/Fe3 O4 @Quercetin NC (G/S/Fe3 O4 @QC) because the magnetic properties of Fe3 O4 decreased with the addition of G/S@QC. Stability and particle size were determined by zeta potential and Dynamic light scattering (DLS). The percentage of drug loading and encapsulation efficiency of QC in the NC was 46.25 % and 87 %, respectively. QC profile release in acidic and natural environments showed controlled release and pH sensitivity of the NC. Cytotoxicity of L929 and HepG2 treated cells with the G/S/Fe3 O4 @QC was investigated by MTT staining, which agreed with the flow cytometry result. The results of Flowcytometry and MTT showed 43.5 % apoptosis and 42 % cytotoxicity in treated HepG2 cells by G/S/Fe3 O4 @QC, while it was not toxic to L929 normal cells. According to the results, G/S/Fe3 O4 @QC is a suitable NC for the targeted delivery of QC as a drug against HepG2 cancer cells., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF